New World and Old World Leishmania Infections: A Practical Review

Dermatologic Clinics

Volumn 33, Issue 3, 2015, Pages 579-593

  Kevric, Ines ^a   Cappel, Mark A ^a   Keeling, James H ^a  

^a MAYO CLINIC   (United States)

Author keywords

Cutaneous leishmaniasis; Leishmania infection; Leishmaniasis; Mucocutaneous leishmaniasis

Indexed keywords

ALLOPURINOL; AMPHOTERICIN B; AMPHOTERICIN B DEOXYCHOLATE; AMPHOTERICIN B LIPID COMPLEX; AZITHROMYCIN; FLUCONAZOLE; IMIQUIMOD; ITRACONAZOLE; KETOCONAZOLE; LIQUID NITROGEN; MEGLUMINE ANTIMONATE; MILTEFOSINE; PAROMOMYCIN; PENTAMIDINE; PENTOXIFYLLINE; PLACEBO; POSACONAZOLE; STIBOGLUCONATE SODIUM; AMPHOTERICIN B, DEOXYCHOLATE DRUG COMBINATION; ANTIMONY GLUCONATE; ANTIPROTOZOAL AGENT; DEOXYCHOLIC ACID; DRUG COMBINATION; PHOSPHORYLCHOLINE;

CARDIOTOXICITY; CLINICAL FEATURE; CREATINE KINASE BLOOD LEVEL; CREATININE BLOOD LEVEL; DIARRHEA; DIFFUSE CUTANEOUS LEISHMANIASIS; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; GASTROINTESTINAL DISEASE; HEADACHE; HISTOPATHOLOGY; HUMAN; HYPERTHERMIC THERAPY; HYPOTENSION; IMMUNOASSAY; IMMUNOLOGY; INFECTION PREVENTION; LEISHMANIA BRAZILIENSIS; LEISHMANIA DONOVANI; LEISHMANIA MEXICANA; LEISHMANIA TROPICA; LEISHMANIASIS; LIVER TOXICITY; MOTION SICKNESS; MUCOCUTANEOUS LEISHMANIASIS; NAUSEA; NEPHROTOXICITY; PATHOGENESIS; PHOTODYNAMIC THERAPY; PHYSIOTHERAPY; PRIORITY JOURNAL; PRURITUS; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SIDE EFFECT; SKIN BIOPSY; SKIN IRRITATION; SKIN LEISHMANIASIS; VISCERAL LEISHMANIASIS; VOMITING; ANALOGS AND DERIVATIVES; DRUG COMBINATION; GENETICS; INCIDENCE; LEISHMANIASIS, DIFFUSE CUTANEOUS; LEISHMANIASIS, MUCOCUTANEOUS; LEISHMANIASIS, VISCERAL; POLYMERASE CHAIN REACTION; TRAVEL;

AMPHOTERICIN B; ANTIMONY SODIUM GLUCONATE; ANTIPROTOZOAL AGENTS; DEOXYCHOLIC ACID; DRUG COMBINATIONS; HUMANS; INCIDENCE; LEISHMANIA BRAZILIENSIS; LEISHMANIA DONOVANI; LEISHMANIA MEXICANA; LEISHMANIA TROPICA; LEISHMANIASIS, DIFFUSE CUTANEOUS; LEISHMANIASIS, MUCOCUTANEOUS; LEISHMANIASIS, VISCERAL; PHOSPHORYLCHOLINE; POLYMERASE CHAIN REACTION; TRAVEL;

EID: 84937115700     PISSN: 07338635     EISSN: 15580520     Source Type: Journal    
DOI: 10.1016/j.det.2015.03.018     Document Type: Review

References (90)

1. den Boer M., Argaw D., Jannin J., et al. Leishmaniasis impact and treatment access. Clin Microbiol Infect 2011, 17(10):1471-1477.
2. Leishmaniasis. 2014. Available at: Accessed April 02, 2014. http://www.who.int/topics/leishmaniasis/en/.
3. Parasites. Leishmaniasis. 2013. Available at: Accessed April 02, 2014. http://www.cdc.gov/parasites/leishmaniasis/index.html.
4. Sutherst R.W. Global change and human vulnerability to vector-borne diseases. Clin Microbiol Rev 2004, 17(1):136-173.
5. Pavli A., Maltezou H.C. Leishmaniasis, an emerging infection in travelers. Int J Infect Dis 2010, 14(12):e1032-e1039.
6. Lawn S.D., Whetham J., Chiodini P.L., et al. New World mucosal and cutaneous leishmaniasis: an emerging health problem among British travellers. QJM 2004, 97(12):781-788.
7. El Hajj L., Thellier M., Carrière J., et al. Localized cutaneous leishmaniasis imported into Paris: a review of 39 cases. Int J Dermatol 2004, 43(2):120-125.
8. Malik A.N., John L., Bruceson A.D., et al. Changing pattern of visceral leishmaniasis, United Kingdom, 1985-2004. Emerg Infect Dis 2006, 12(8):1257-1259.
9. Wright N.A., Davis L.E., Aftergut K.S., et al. Cutaneous leishmaniasis in Texas: a northern spread of endemic areas. JAm Acad Dermatol 2008, 58(4):650-652.
10. Melby P.C., Kreutzer R.D., McMahon-Pratt D., et al. Cutaneous leishmaniasis: review of 59 cases seen at the National Institutes of Health. Clin Infect Dis 1992, 15(6):924-937.
11. Weitzel T., Mühlberger N., Jelinek T., et al. Imported leishmaniasis in Germany 2001-2004: data of the SIMPID surveillance network. Eur J Clin Microbiol Infect Dis 2005, 24(7):471-476.
12. Cardo L.J. Leishmania: risk to the blood supply. Transfusion 2006, 46(9):1641-1645.
13. Figueiro-Filho E.A., Duarte G., El-Beitune P., et al. Visceral leishmaniasis (kala-azar) and pregnancy. Infect Dis Obstet Gynecol 2004, 12(1):31-40.
14. Akilov O.E., Khachemoune A., Hasan T. Clinical manifestations and classification of Old World cutaneous leishmaniasis. Int J Dermatol 2007, 46(2):132-142.
15. Banuls A.L., Hide M., Prugnolle F. Leishmania and the leishmaniases: a parasite genetic update and advances in taxonomy, epidemiology and pathogenicity in humans. Adv Parasitol 2007, 64:1-109.
16. Kaye P., Scott P. Leishmaniasis: complexity at the host-pathogen interface. Nat Rev Microbiol 2011, 9(8):604-615.
17. Lupi O., Bartlett B.L., Haugen R.N., et al. Tropical dermatology: tropical diseases caused by protozoa. JAm Acad Dermatol 2009, 60(6):897-925. [quiz: 926-8].
18. Schwartz E., Hatz C., Blum J. New world cutaneous leishmaniasis in travellers. Lancet Infect Dis 2006, 6(6):342-349.
19. Blum J., Desjeux P., Schwartz E., et al. Treatment of cutaneous leishmaniasis among travellers. JAntimicrob Chemother 2004, 53(2):158-166.
20. Soong L., Henard C.A., Melby P.C. Immunopathogenesis of non-healing American cutaneous leishmaniasis and progressive visceral leishmaniasis. Semin Immunopathol 2012, 34(6):735-751.
21. Nylen S., Eidsmo L. Tissue damage and immunity in cutaneous leishmaniasis. Parasite Immunol 2012, 34(12):551-561.
22. Awasthi A., Mathur R.K., Saha B. Immune response to Leishmania infection. Indian J Med Res 2004, 119(6):238-258.
23. Iftikhar N., Bari I., Ejaz A. Rare variants of cutaneous leishmaniasis: whitlow, paronychia, and sporotrichoid. Int J Dermatol 2003, 42(10):807-809.
24. Salmanpour R., Handjani F., Zerehsaz F., et al. Erysipeloid leishmaniasis: an unusual clinical presentation. Eur J Dermatol 1999, 9(6):458-459.
25. Rubio F.A., Robayna G., Herranz P., et al. Leishmaniasis presenting as a psoriasiform eruption in AIDS. Br J Dermatol 1997, 136(5):792-794.
26. Bogdan C. Leishmaniasis in rheumatology, haematology and oncology: epidemiological, immunological and clinical aspects and caveats. Ann Rheum Dis 2012, 71(Suppl 2):i60-i66.
27. Alvar J., Aparicio P., Aseffa A., et al. The relationship between leishmaniasis and AIDS: the second 10 years. Clin Microbiol Rev 2008, 21(2):334-359. table of contents.
28. Xynos I.D., Tektonidou M.G., Pikazis D., et al. Leishmaniasis, autoimmune rheumatic disease, and anti-tumor necrosis factor therapy, Europe. Emerg Infect Dis 2009, 15(6):956-959.
29. Antinori S., Cascio A., Parravicini C., et al. Leishmaniasis among organ transplant recipients. Lancet Infect Dis 2008, 8(3):191-199.
30. Jirmanus L., Glesby M.J., Guimarães L.H., et al. Epidemiological and clinical changes in American tegumentary leishmaniasis in an area of Leishmania (Viannia) braziliensis transmission over a 20-year period. Am J Trop Med Hyg 2012, 86(3):426-433.
31. Perez-Ayala A., Norman F., Pérez-Molina J.A., et al. Imported leishmaniasis: a heterogeneous group of diseases. JTravel Med 2009, 16(6):395-401.
32. Machado-Coelho G.L., Caiaffa W.T., Genaro O., et al. Risk factors for mucosal manifestation of American cutaneous leishmaniasis. Trans R Soc Trop Med Hyg 2005, 99(1):55-61.
33. Petzl-Erler M.L., Belich M.P., Queiroz-Telles F. Association of mucosal leishmaniasis with HLA. Hum Immunol 1991, 32(4):254-260.
34. Maltezou H.C., Siafas C., Mavrikou M., et al. Visceral leishmaniasis during childhood in southern Greece. Clin Infect Dis 2000, 31(5):1139-1143.
35. Berman J.D. Human leishmaniasis: clinical, diagnostic, and chemotherapeutic developments in the last 10 years. Clin Infect Dis 1997, 24(4):684-703.
36. Seaton R.A., Morrison J., Man I., et al. Out-patient parenteral antimicrobial therapy: a viable option for the management of cutaneous leishmaniasis. QJM 1999, 92(11):659-667.
37. Weigle K.A., de Dávalos M., Heredia P., et al. Diagnosis of cutaneous and mucocutaneous leishmaniasis in Colombia: a comparison of seven methods. Am J Trop Med Hyg 1987, 36(3):489-496.
38. Bolognia J., Jorizzo J., Schaffer J. Protozoa and worms: leishmaniasis. Dermatology 2012, 1391-1397. Elsevier, Philadelphia, PA. S. Nelson, K. Warschaw (Eds.).
39. Oliveira J.G., Novais F.O., de Oliveira C.I., et al. Polymerase chain reaction (PCR) is highly sensitive for diagnosis of mucosal leishmaniasis. Acta Trop 2005, 94(1):55-59.
40. Convit J., Ulrich M., Fernández C.T., et al. The clinical and immunological spectrum of American cutaneous leishmaniasis. Trans R Soc Trop Med Hyg 1993, 87(4):444-448.
41. Arana B.A., Roca M., Rizzo N.R., et al. Evaluation of a standardized leishmanin skin test in Guatemala. Trans R Soc Trop Med Hyg 1999, 93(4):394-396.
42. Gonzalez U., Pinart M., Rengifo-Pardo M., et al. Interventions for American cutaneous and mucocutaneous leishmaniasis. Cochrane Database Syst Rev 2009, (2). CD004834.
43. Gonzalez U., Pinart M., Reveiz L., et al. Interventions for Old World cutaneous leishmaniasis. Cochrane Database Syst Rev 2008, (4). CD005067.
44. Andrade-Narvaez F.J., Vargas-González A., Canto-Lara S.B., et al. Clinical picture of cutaneous leishmaniases due to Leishmania (Leishmania) mexicana in the Yucatan peninsula, Mexico. Mem Inst Oswaldo Cruz 2001, 96(2):163-167.
45. Hepburn N.C. Cutaneous leishmaniasis: an overview. JPostgrad Med 2003, 49(1):50-54.
46. Murray H.W., Berman J.D., Davies C.R., et al. Advances in leishmaniasis. Lancet 2005, 366(9496):1561-1577.
47. Murray H.W. Leishmaniasis in the United States: treatment in 2012. Am J Trop Med Hyg 2012, 86(3):434-440.
48. Maltezou H.C. Visceral leishmaniasis: advances in treatment. Recent Pat Antiinfect Drug Discov 2008, 3(3):192-198.
49. Nacher M., Carme B., Sainte Marie D., et al. Influence of clinical presentation on the efficacy of a short course of pentamidine in the treatment of cutaneous leishmaniasis in French Guiana. Ann Trop Med Parasitol 2001, 95(4):331-336.
50. Andersen E.M., Cruz-Saldarriaga M., Llanos-Cuentas A., et al. Comparison of meglumine antimoniate and pentamidine for Peruvian cutaneous leishmaniasis. Am J Trop Med Hyg 2005, 72(2):133-137.
51. Herwaldt B.L., Berman J.D. Recommendations for treating leishmaniasis with sodium stibogluconate (Pentostam) and review of pertinent clinical studies. Am J Trop Med Hyg 1992, 46(3):296-306.
52. Aronson N.E., Wortmann G.W., Johnson S.C., et al. Safety and efficacy of intravenous sodium stibogluconate in the treatment of leishmaniasis: recent U.S. military experience. Clin Infect Dis 1998, 27(6):1457-1464.
53. Davidson R.N. Practical guide for the treatment of leishmaniasis. Drugs 1998, 56(6):1009-1018.
54. Antezana G., Zeballos R., Mendoza C., et al. Electrocardiographic alterations during treatment of mucocutaneous leishmaniasis with meglumine antimoniate and allopurinol. Trans R Soc Trop Med Hyg 1992, 86(1):31-33.
55. Sundar S., Chakravarty J., Rai V.K., et al. Amphotericin B treatment for Indian visceral leishmaniasis: response to 15 daily versus alternate-day infusions. Clin Infect Dis 2007, 45(5):556-561.
56. Olliaro P.L., Guerin P.J., Gerstl S., et al. Treatment options for visceral leishmaniasis: a systematic review of clinical studies done in India, 1980-2004. Lancet Infect Dis 2005, 5(12):763-774.
57. Harms G., Schonian G., Feldmeier H. Leishmaniasis in Germany. Emerg Infect Dis 2003, 9(7):872-875.
58. de Paula C.D., Sampaio J.H., Cardoso D.R., et al. Acomparative study between the efficacy of pentamidine isothionate given in three doses for one week and N-methil-glucamine in a dose of 20 mg SbV/day for 20 days to treat cutaneous leishmaniasis. Rev Soc Bras Med Trop 2003, 36(3):365-371. [in Portuguese].
59. Soto-Mancipe J., Grogl M., Berman J.D. Evaluation of pentamidine for the treatment of cutaneous leishmaniasis in Colombia. Clin Infect Dis 1993, 16(3):417-425.
60. Jha T.K., Sundar S., Thakur C.P., et al. Miltefosine, an oral agent, for the treatment of Indian visceral leishmaniasis. NEngl J Med 1999, 341(24):1795-1800.
61. Soto J., Toledo J., Valda L., et al. Treatment of Bolivian mucosal leishmaniasis with miltefosine. Clin Infect Dis 2007, 44(3):350-356.
62. Soto J., Arana B.A., Toledo J., et al. Miltefosine for new world cutaneous leishmaniasis. Clin Infect Dis 2004, 38(9):1266-1272.
63. Faghihi G., Tavakoli-kia R. Treatment of cutaneous leishmaniasis with either topical paromomycin or intralesional meglumine antimoniate. Clin Exp Dermatol 2003, 28(1):13-16.
64. Arana B.A., Mendoza C.E., Rizzo N.R., et al. Randomized, controlled, double-blind trial of topical treatment of cutaneous leishmaniasis with paromomycin plus methylbenzethonium chloride ointment in Guatemala. Am J Trop Med Hyg 2001, 65(5):466-470.
65. Armijos R.X., Weigel M.M., Calvopiña M., et al. Comparison of the effectiveness of two topical paromomycin treatments versus meglumine antimoniate for New World cutaneous leishmaniasis. Acta Trop 2004, 91(2):153-160.
66. Alrajhi A.A., Ibrahim E.A., De Vol E.B., et al. Fluconazole for the treatment of cutaneous leishmaniasis caused by Leishmania major. NEngl J Med 2002, 346(12):891-895.
67. Morizot G., Delgiudice P., Caumes E., et al. Healing of Old World cutaneous leishmaniasis in travelers treated with fluconazole: drug effect or spontaneous evolution?. Am J Trop Med Hyg 2007, 76(1):48-52.
68. Aerts O., Duchateau N., Willemse P., et al. Cutaneous leishmaniasis: treatment with low-dose oral fluconazole with an excellent cosmetic result. Pediatr Dermatol 2014, 32(1):154-155.
69. Daly K., De Lima H., Kato H., et al. Intermediate cutaneous leishmaniasis caused by Leishmania (Viannia) braziliensis successfully treated with fluconazole. Clin Exp Dermatol 2014, 39(6):708-712.
70. de Macedo-Silva S.T., Urbina J.A., de Souza W., et al. Invitro activity of the antifungal azoles itraconazole and posaconazole against Leishmania amazonensis. PLoS One 2013, 8(12):e83247.
71. Khazaeli P., Sharifi I., Talebian E., et al. Anti-leishmanial effect of itraconazole niosome on invitro susceptibility of Leishmania tropica. Environ Toxicol Pharmacol 2014, 38(1):205-211.
72. Teixeira A.C., Paes M.G., Guerra Jde O., et al. Low efficacy of azithromycin to treat cutaneous leishmaniasis in Manaus, AM, Brazil. Rev Inst Med Trop Sao Paulo 2007, 49(4):235-238.
73. Layegh P., Yazdanpanah M.J., Vosugh E.M., et al. Efficacy of azithromycin versus systemic meglumine antimoniate (Glucantime) in the treatment of cutaneous leishmaniasis. Am J Trop Med Hyg 2007, 77(1):99-101.
74. Silva-Vergara M.L., Silva Lde A., Maneira F.R., et al. Azithromycin in the treatment of mucosal leishmaniasis. Rev Inst Med Trop Sao Paulo 2004, 46(3):175-177.
75. Buates S., Matlashewski G. Treatment of experimental leishmaniasis with the immunomodulators imiquimod and S-28463: efficacy and mode of action. JInfect Dis 1999, 179(6):1485-1494.
76. Miranda-Verastegui C., Llanos-Cuentas A., Arévalo I., et al. Randomized, double-blind clinical trial of topical imiquimod 5% with parenteral meglumine antimoniate in the treatment of cutaneous leishmaniasis in Peru. Clin Infect Dis 2005, 40(10):1395-1403.
77. Arevalo I., Tulliano G., Quispe A., et al. Role of imiquimod and parenteral meglumine antimoniate in the initial treatment of cutaneous leishmaniasis. Clin Infect Dis 2007, 44(12):1549-1554.
78. Martinez S., Gonzalez M., Vernaza M.E. Treatment of cutaneous leishmaniasis with allopurinol and stibogluconate. Clin Infect Dis 1997, 24(2):165-169.
79. Martinez S., Marr J.J. Allopurinol in the treatment of American cutaneous leishmaniasis. NEngl J Med 1992, 326(11):741-744.
80. Velez I., Agudelo S., Hendrickx E., et al. Inefficacy of allopurinol as monotherapy for Colombian cutaneous leishmaniasis. A randomized, controlled trial. Ann Intern Med 1997, 126(3):232-236.
81. Asilian A., Jalayer T., Nilforooshzadeh M., et al. Treatment of cutaneous leishmaniasis with aminosidine (paromomycin) ointment: double-blind, randomized trial in the Islamic Republic of Iran. Bull World Health Organ 2003, 81(5):353-359.
82. Asilian A., Davami M. Comparison between the efficacy of photodynamic therapy and topical paromomycin in the treatment of Old World cutaneous leishmaniasis: a placebo-controlled, randomized clinical trial. Clin Exp Dermatol 2006, 31(5):634-637.
83. Firooz A., Khamesipour A., Ghoorchi M.H., et al. Imiquimod in combination with meglumine antimoniate for cutaneous leishmaniasis: a randomized assessor-blind controlled trial. Arch Dermatol 2006, 142(12):1575-1579.
84. Mohebali M., Fotouhi A., Hooshmand B., et al. Comparison of miltefosine and meglumine antimoniate for the treatment of zoonotic cutaneous leishmaniasis (ZCL) by a randomized clinical trial in Iran. Acta Trop 2007, 103(1):33-40.
85. Reithinger R., Mohsen M., Wahid M., et al. Efficacy of thermotherapy to treat cutaneous leishmaniasis caused by Leishmania tropica in Kabul, Afghanistan: a randomized, controlled trial. Clin Infect Dis 2005, 40(8):1148-1155.
86. Sadeghian G., Nilforoushzadeh M.A. Effect of combination therapy with systemic glucantime and pentoxifylline in the treatment of cutaneous leishmaniasis. Int J Dermatol 2006, 45(7):819-821.
87. Saenz R.E., Paz H., Berman J.D. Efficacy of ketoconazole against Leishmania braziliensis panamensis cutaneous leishmaniasis. Am J Med 1990, 89(2):147-155.
88. Soto J., Valda-Rodriquez L., Toledo J., et al. Comparison of generic to branded pentavalent antimony for treatment of new world cutaneous leishmaniasis. Am J Trop Med Hyg 2004, 71(5):577-581.
89. Mosleh I.M., Geith E., et al. Efficacy of a weekly cryotherapy regimen to treat Leishmania major cutaneous leishmaniasis. Am J Acad Dermatol 2008, 58(4):617-624.
90. Oliveira-Neto M.P., Schuback A., et al. Intralesional therapy of American cutaneous leishmaniasis with pentavalent antimony in Rio de janeiro, Brazil - an area of leishmania (V.) braziliensis transmission. Int J Derm 1997, 36:463-468.